BBB opening with focused ultrasound in nonhuman primates and Parkinson's disease patients: Targeted AAV vector delivery and PET imaging.
Authors: Blesa J, Pineda-Pardo JA, Inoue KI, Gasca-Salas C, Balzano T, Del Rey NL, Reinares-Sebastián A, Esteban-García N, Rodríguez-Rojas R, Márquez R, Ciorraga M, Del Álamo M, García-Cañamaque L, Ruiz de Aguiar S, Rachmilevitch I, Trigo-Damas I, Takada M, Obeso JA
Intracerebral vector delivery in nonhuman primates has been a major challenge. We report successful blood-brain barrier opening and focal delivery of adeno-associated virus serotype 9 vectors into brain regions involved in Parkinson's disease using low-intensity focus ultrasound in adult macaque monkeys. Openings were well tolerated with generally no associated abnormal magnetic resonance imaging signals. Neuronal green fluorescent protein expression was observed specifically in regions with confirmed blood-brain barrier opening. Similar blood-brain barrier openings were safely demonstrated in three patients with Parkinson's disease. In these patients and in one monkey, blood-brain barrier opening was followed by <sup>18</sup>F-Choline uptake in the putamen and midbrain regions based on positron emission tomography. This indicates focal and cellular binding of molecules that otherwise would not enter the brain parenchyma. The less-invasive nature of this methodology could facilitate focal viral vector delivery for gene therapy and might allow early and repeated interventions to treat neurodegenerative disorders.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To demonstrate that low‑intensity focused ultrasound can safely open the blood–brain barrier to enable focal delivery of AAV9 viral vectors into Parkinson’s disease–relevant brain regions in nonhuman primates and humans.
Animal model / Human subject
Macaque monkey (nonhuman primate); strain: not specified; age: adult; sex: not specified. Also included human patients (Homo sapiens) for safety/demonstration: strain: N/A; age: not specified; sex: not specified.
Disease model
Parkinson's disease
Targeted brain region(s)
Midbrain
Cargo name and characteristics
Adeno-associated virus serotype 9 (AAV9) viral vector encoding green fluorescent protein (GFP) transgene (viral gene therapy vector)
Outcomes and Safety
Summary of Outcomes
MRI-guided transcranial low-intensity focused ultrasound (LIFU) with microbubbles produced safe, focal and reversible BBB openings in macaques and three PD patients, enabling focal AAV9 (AAV9-PHPeB/AAV9.2-PHPeB) delivery that yielded neuron-specific GFP expression in opened regions and correlated 18F‑Choline PET uptake; preexisting neutralizing antibodies prevented transduction in some animals. Successful ultrasound approaches included small focal grids (2x2 or 1x2) at 2 mm spacing for moderate openings and denser targeting (1 mm spacing across multiple axial planes, multitargeted/bilateral sonications) to achieve large-volume putamen openings (up to ~806 mm3).
Duration of biological effect
4 weeks
Safety-related matter
LIFU BBB openings were well tolerated in NHPs and three PD patients with no acute neurological or behavioral deficits, no MRI evidence of edema, microhemorrhage, or infarction, generally no histopathological tissue damage, and reversible BBB permeability. However, two monkeys showed minor, localized inflammatory changes (M4: slight perivascular GFAP increase; M3: moderate focal increases in GFAP and Iba1 after the largest opening), confined to small regions without apparent neuronal loss.
Brain Region
Ultrasound Parameters
Focal Characteristics
Focal depth: None; Focal length: None; Aperture size: None
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search